DGIdb - OXYBUTYNIN Drug Record

OXYBUTYNIN chembl:CHEMBL1231 Approved

Alternate Names:

ANTUROL
PROMICTULINE
OXYTROL
OXYBUTYNIN
CONTIMIN 5
KENTERA
CYSTRIN
DITROPAN XL
DITROPAN
LYRINEL XL
URIMIN
OXYTROL FOR WOMEN
CONTIMIN 2.5

Drug Info:

Drug Class	antispasmodics
Year of Approval	1975
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of overactive bladder
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	for treatment of incontinence

(1 More Sources)

Publications:

Sinha et al., 2010, AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder., Br. J. Pharmacol.
Baldwin et al., 2009, Transdermal oxybutynin., Drugs
Oki et al., 2007, Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder., J. Urol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Maruyama et al., 2006, Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder., J. Urol.
Ito et al., 2009, Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice., Eur. J. Pharmacol.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Yarker YE et al., 1995, Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability., Drugs Aging
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Dmochowski, 2005, Improving the tolerability of anticholinergic agents in the treatment of overactive bladder., Drug Saf
Nelson et al., 2006, Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor., J. Pharmacol. Exp. Ther.

OXYBUTYNIN CHRM2

Interaction Score: 2.18

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name AA-2010

Novel drug target Established target

Trial Name AP-1034,Anturol

PMIDs:
19446545 15963006 17222678 16188951 20590605 7620236

Sources:
TdgClinicalTrial ChemblInteractions TEND
OXYBUTYNIN CHRM3

Interaction Score: 2.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Muscarinic acetylcholine receptor M3 antagonist

Direct Interaction yes

Trial Name transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique

PMIDs:
20590605 19275276 17222678 11752352 16406943 19446545 17016423 17139284 7620236

Sources:
TdgClinicalTrial ChemblInteractions TEND
OXYBUTYNIN CHRM1

Interaction Score: 1.18

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name AA-2010

Novel drug target Established target

Trial Name AP-1034,Anturol

PMIDs:
20590605 17222678 17016423 17139284 16406943 7620236

Sources:
TdgClinicalTrial TEND
OXYBUTYNIN CYP2D6

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
OXYBUTYNIN CYP3A4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: OXYBUTYNIN
- Version: 01-August-2011
Alternate Names:

OXYBUTYNIN Primary Drug Name

Drug Info:

Year of Approval 1975

Drug Class antispasmodics

Publications:
TdgClinicalTrial: OXYBUTYNIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of incontinence

Drug Class Small molecule

FDA Approval not approved

Publications:
DTC: OXYBUTYNIN
- Version: 02-September-2020
Alternate Names:

CHEMBL1231 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
ChemblDrugs: chembl:CHEMBL1231
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1231
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	AA-2010
Novel drug target	Established target
Trial Name	AP-1034,Anturol

Mechanism of Interaction	Muscarinic acetylcholine receptor M3 antagonist
Direct Interaction	yes
Trial Name	transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique

OXYBUTYNIN Drug Record

OXYBUTYNIN chembl:CHEMBL1231 Approved

Alternate Names:

Drug Info:

Publications:

OXYBUTYNIN CHRM2

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name AA-2010 Novel drug target Established target Trial Name AP-1034,Anturol

PMIDs: 19446545 15963006 17222678 16188951 20590605 7620236

Sources: TdgClinicalTrial ChemblInteractions TEND

OXYBUTYNIN CHRM3

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Muscarinic acetylcholine receptor M3 antagonist Direct Interaction yes Trial Name transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique

PMIDs: 20590605 19275276 17222678 11752352 16406943 19446545 17016423 17139284 7620236

Sources: TdgClinicalTrial ChemblInteractions TEND

OXYBUTYNIN CHRM1

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name AA-2010 Novel drug target Established target Trial Name AP-1034,Anturol

PMIDs: 20590605 17222678 17016423 17139284 16406943 7620236

Sources: TdgClinicalTrial TEND

OXYBUTYNIN CYP2D6

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

OXYBUTYNIN CYP3A4

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: OXYBUTYNIN

Alternate Names: OXYBUTYNIN Primary Drug Name

Drug Info: Year of Approval 1975 Drug Class antispasmodics

Publications:

TdgClinicalTrial: OXYBUTYNIN

Alternate Names:

Drug Info: Drug Indications for treatment of incontinence Drug Class Small molecule FDA Approval not approved

Publications:

DTC: OXYBUTYNIN

Alternate Names: CHEMBL1231 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

ChemblDrugs: chembl:CHEMBL1231

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1231

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name AA-2010

Novel drug target Established target

Trial Name AP-1034,Anturol

PMIDs:
19446545 15963006 17222678 16188951 20590605 7620236

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Muscarinic acetylcholine receptor M3 antagonist

Direct Interaction yes

Trial Name transdermal oxybutynin patch, oxybutynin topical gel,Oxytrol, Kentera, Gelnique

PMIDs:
20590605 19275276 17222678 11752352 16406943 19446545 17016423 17139284 7620236

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name AA-2010

Novel drug target Established target

Trial Name AP-1034,Anturol

PMIDs:
20590605 17222678 17016423 17139284 16406943 7620236

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

OXYBUTYNIN Primary Drug Name

Drug Info:

Year of Approval 1975

Drug Class antispasmodics

Drug Info:

Drug Indications for treatment of incontinence

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL1231 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol